Exelixis (EXEL) Share-based Compensation (2010 - 2026)
Exelixis' (EXEL) quarterly Share-based Compensation came in at $34.2 million in Q2 2026, up 52.03% year-on-year from $22.5 million in Q2 2025, and up 70.33% quarter-over-quarter from $20.1 million in Q1 2026.
Exelixis (EXEL) Share-based Compensation (2010 - 2026) Analysis & Trends
Exelixis' Share-based Compensation history runs 17 years deep, the most recent figure standing at $34.2 million for Q2 2026.
- On a quarterly basis, Share-based Compensation rose 52.03% year-over-year to $34.2 million in Q2 2026; TTM through Apr 2026 was $124.7 million, a 566.26% increase from a year earlier, with the FY2026 full-year figure at $113.0 million, up 637.82% from the prior year.
- Share-based Compensation climbed to $34.2 million in Q2 2026 per EXEL's latest filing, from $20.1 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $91.5 million in Q4 2022 and bottomed at -$52.2 million in Q1 2025.
- The 5-year median for Share-based Compensation is $19.1 million (2024), against an average of $16.9 million.
- Across the five-year window, Share-based Compensation plunged 1468.43% in 2022 and jumped 4282.35% in 2025, its largest moves.
- Year by year, Share-based Compensation stood at $91.5 million in 2022, then sank by 107.12% to -$6.5 million in 2023, then jumped by 828.94% to $47.5 million in 2024, then tumbled by 34.95% to $30.9 million in 2025, then climbed by 10.83% to $34.2 million in 2026.
- Per Business Quant, the three latest EXEL Share-based Compensation figures stand at $34.2 million (Q2 2026), $20.1 million (Q1 2026), and $30.9 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn | 34.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 34.23 Mn |
| Apr 3, 2026 | 34.23 Mn |
| Jan 2, 2026 | 20.10 Mn |
| Jan 2, 2026 | 20.10 Mn |
| Oct 3, 2025 | 30.89 Mn |
| Oct 3, 2025 | 30.89 Mn |
| Jul 4, 2025 | 39.49 Mn |
| Jul 4, 2025 | 39.49 Mn |
| Apr 4, 2025 | 22.52 Mn |
| Apr 4, 2025 | 22.52 Mn |
| Jan 3, 2025 | -52.18 Mn |
| Jan 3, 2025 | -52.18 Mn |
| Sep 27, 2024 | 47.48 Mn |
| Sep 27, 2024 | 47.48 Mn |
| Jun 28, 2024 | 901,000.00 |
| Jun 28, 2024 | 901,000.00 |
| Mar 29, 2024 | 19.11 Mn |
| Mar 29, 2024 | 19.11 Mn |
| Dec 29, 2023 | -6.51 Mn |
| Dec 29, 2023 | -6.51 Mn |